Janney Montgomery Scott set a $170.00 price objective on bluebird bio (NASDAQ:BLUE) in a research report sent to investors on Monday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other analysts also recently commented on BLUE. BidaskClub raised shares of bluebird bio from a strong sell rating to a sell rating in a research report on Friday, November 30th. Zacks Investment Research downgraded shares of bluebird bio from a buy rating to a hold rating in a research report on Friday, November 30th. Cantor Fitzgerald set a $122.00 price objective on shares of bluebird bio and gave the stock a sell rating in a research report on Monday, August 6th. Oppenheimer reaffirmed a hold rating on shares of bluebird bio in a research report on Tuesday, November 27th. Finally, Maxim Group reaffirmed a hold rating on shares of bluebird bio in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seventeen have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $194.80.
NASDAQ:BLUE opened at $108.85 on Monday. The company has a market cap of $6.22 billion, a price-to-earnings ratio of -14.12 and a beta of 2.37. bluebird bio has a fifty-two week low of $100.99 and a fifty-two week high of $236.17.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping the consensus estimate of ($2.90) by $0.17. The company had revenue of $11.50 million during the quarter, compared to the consensus estimate of $6.90 million. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The company’s quarterly revenue was up 49.2% on a year-over-year basis. During the same quarter last year, the firm posted ($1.73) EPS. Equities research analysts forecast that bluebird bio will post -10.71 earnings per share for the current fiscal year.
In related news, insider Jeffrey T. Walsh sold 1,500 shares of bluebird bio stock in a transaction on Monday, September 10th. The shares were sold at an average price of $150.16, for a total value of $225,240.00. Following the completion of the sale, the insider now owns 36,995 shares of the company’s stock, valued at approximately $5,555,169.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 1,890 shares of bluebird bio stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $113.83, for a total transaction of $215,138.70. Following the completion of the sale, the chief operating officer now directly owns 15,610 shares of the company’s stock, valued at approximately $1,776,886.30. The disclosure for this sale can be found here. In the last three months, insiders sold 21,490 shares of company stock valued at $2,901,186. 3.00% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of BLUE. Capital International Investors grew its position in bluebird bio by 188.6% in the 3rd quarter. Capital International Investors now owns 3,260,636 shares of the biotechnology company’s stock valued at $476,053,000 after purchasing an additional 2,130,927 shares during the period. Capital World Investors grew its position in bluebird bio by 37.4% in the 3rd quarter. Capital World Investors now owns 3,425,687 shares of the biotechnology company’s stock valued at $500,150,000 after purchasing an additional 931,932 shares during the period. FMR LLC grew its position in bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock valued at $1,186,058,000 after purchasing an additional 605,797 shares during the period. Capital Research Global Investors grew its position in bluebird bio by 8.1% in the 3rd quarter. Capital Research Global Investors now owns 6,634,317 shares of the biotechnology company’s stock valued at $968,610,000 after purchasing an additional 494,787 shares during the period. Finally, Vanguard Group Inc. grew its position in bluebird bio by 10.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after purchasing an additional 422,866 shares during the period.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Read More: Cash Flow
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.